NVAX Novavax
- 14.400
- -0.650-4.32%
- 14.350
- -0.050-0.35%
Novavax News
Fifth Times a Charm, But Just for the Nasdaq | Wall Street Today
Major stock indexes pulled back Friday, but the Nasdaq still climbed to a Fifth closing high.
Novavax Files Emergency Use Authorization Amendment For Updated COVID-19 Vaccine
Novavax (NVAX) said Friday it has filed an Emergency Use Authorization amendment to the US Food and Drug Administration for its updated JN.1 COVID-19 vaccine for individuals aged 12 and older. Novavax
Express News | Novavax Shares Down 1.5% in Volume Spike After It Seeks FDA Approval for Updated Covid Vaccine
Novavax Seeks FDA Authorization for Updated JN.1 COVID Shot
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
Express News | FDA Says On June 13 Updates Advice To Manufacturers Of Covid-19 Vaccines (2024-2025 Formula): If Feasible Use KP.2 Strain Of JN.1-Lineage
Express News | Novavax - Submitted Amendment to Emergency Use Authorization to U.S. FDA for Updated Jn.1 Covid-19 Vaccine (Nvx-Cov2705) for People Aged 12 & Older
Express News | Novavax Inc: Intends to Have Its Vaccine in Pre-Filled Syringes Available in U.S. for Immediate Release Post-Authorization
Express News | Novavax Inc - Also Working With Other Regulatory Authorities Globally on Authorization or Approval of Its Jn.1 Covid-19 Vaccine
Express News | Novavax Inc - Novavax's Filing Is Aligned With FDA, EMA and Who Global Recommendations on Vaccine Composition
Express News | Novavax Inc - Novavax's Jn.1 Covid-19 Vaccine Would Be Only Protein-Based Option Available in U.S.
Express News | Novavax Inc - Intends to Have Doses in U.S. for Distribution by Mid-August
Express News | Novavax Inc - Novavax's Updated Jn.1 Covid-19 Vaccine Is Active Against Current Circulating Strains, Including Kp.2 and Kp.3
Express News | Novavax Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine
Novavax Is Maintained at Neutral by B of A Securities
Novavax Is Maintained at Neutral by B of A Securities
(NVAX) - Analyzing Novavax's Short Interest
Novavax's (NYSE:NVAX) short percent of float has fallen 15.64% since its last report. The company recently reported that it has 38.21 million shares sold short, which is 33.07% of all regular shares t
B of A Securities Maintains Neutral on Novavax, Raises Price Target to $18
B of A Securities analyst Alec Stranahan maintains Novavax (NASDAQ:NVAX) with a Neutral and raises the price target from $12 to $18.
Novavax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/14/2024 25.44% B of A Securities $12 → $18 Maintains Neutral 05/23/2024 102.09% B. Riley Securities $11
Has the Pullback Finally Come? | Herd on Wall Street Podcast
Morning mooers! It is finally Friday, June 14th. The market may actually pull back today after the S&P 500 and Nasdaq hit closing highs for the past four sessions.
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating
BofA Securities analyst Alec Stranahan maintains $Novavax(NVAX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 53.3% and a total average return of 1.5% over the p
Analysis
Price Target
No Data
